top of page
CorNeat Logo Black_Jan 2019.png

Embedded for life!

Permanent Tissue-Integrating Implants

MedTech Innovator logo.png
EIC image.png
Logo for use.png
Anchor 3
רקע כהה למעלה
EverPatch tweezers - large.png

CorNeat EverPatch

FDA cleared.png

Synthetic tissue substitute

רקע כהה למעלה
CorNeat KPro - wavy.png

Revolutionary artificial cornea

רקע כהה למעלה
CorNeat eShunt.png

CorNeat eShunt

Glaucoma drainage device

רקע כהה למעלה

CorNeat gPatch

Permanent periodontal regeneration membrane

Anchor 2

Our Biomimetic Technology 

Biomimetics is the emulation of the models, systems, and elements of nature for the purpose of solving complex human problems*

At CorNeat Vision we aim to significantly impact the well-being of millions by addressing unmet medical needs across several therapeutic fields. Our disruptive platform material technology, the CorNeat EverMatrix™, harnesses the unique characteristics of microstructures of the human body to develop completely synthetic biomimetic implants which mend, reinforce, replace, and bio-integrate with resident tissue.

The EverMatrix™, which was optimized in-vitro and validated in-vivo, enables permanent implants to bio-mechanically integrate with live tissue without triggering an adverse immune system (foreign body) response that leads to encapsulation.


It is 100% synthetic nondegradable porous material that mimics the micro-structure of the Extracellular Matrix (ECM), the natural biological collagen mesh that provides structural and biochemical support to surrounding cells. When implanted, the EverMatrix™ stimulates cellular proliferation leading to progressive tissue integration.

*Vincent, Julian F. V.; et al. (22 August 2006). "Biomimetics: its practice and theory". Journal of the Royal Society Interface. 3 (9): 471–482. doi:10.1098/rsif.2006.0127. PMC 1664643. PMID 16849244.

Use Cases

רקע כהה למעלה

Biomechanical integration of implants to tissue

Permanently attach and integrate synthetic material with live human tissue without rejection

רקע כהה למעלה

Concealment of implants and sensors

Conceal implants and “hide” them from the immune system

רקע כהה למעלה

Fabrication of membranes and tissue barriers

Permanent barriers for controlling tissue regeneration 

רקע כהה למעלה

Soft tissue repair and permanent reinforcment

Provide permanent and firm structural support to soft tissue 

Anchor 1

Our Biomimetic Implants Are

Eye contact2.jpg

Our Mission: Harness Biomimicry for Improving Health

Our mission is to promote health and equality worldwide through innovative biomimetic medical solutions that are widely accessible.

Our goal at CorNeat Vision is to innovate, collaborate and grow in our efforts to introduce biomimetic implants with the aim of permanently resolving medical and surgical challenges in diversified therapeutic fields.

We promote permanent solutions to medical problems through an active learning process, placing the physician's ease-of-use as a top priority.

About CorNeat Vision

CorNeat Vision was established in December 2015 with the goal of developing, producing and introducing to global markets a scalable artificial solution for global corneal blindness, while eliminating the dependency on donor tissue.

Impressed with our pre-clinical trials, which demonstrated progressive and seamless tissue integration of our biomimetic material, the EverMatrix™, the company's scientific advisory board suggested replacing the use  of tectonic tissue grafts with the EverMatrix™ in other ophthalmic surgical procedures. Realizing the potential, we registered IP for additional devices in the ophthalmic space.

In order to fully exploit the business potential of the EverMatrix™ and to maximize its impact on human health, we have expanded our IP and product portfolio and introduced solutions in additional fields of medicine. Our first such product is aimed at permanently resolving gingival recession and replacing the current use of degradable tissue grafts.  

One of our initial products, the CorNeat EverPatch (synthetic tissue substitute) has recently received FDA 510(k) clearance, while the CorNeat KPro (synthetic cornea), is in clinical trials and expected to receive initial marketing approval in 2024.  

Eye surgery
bottom of page